Ashkan Shoamanesh1, Sarah R Preis2, Alexa S Beiser2, Ramachandran S Vasan2, Emelia J Benjamin2, Carlos S Kase2, Philip A Wolf2, Charles DeCarli2, Jose R Romero2, Sudha Seshadri2. 1. From McMaster University (A.S.), Hamilton, Canada; Harvard Medical School (A.S.), Boston; Boston University School of Public Health (S.R.P., A.S.B.); Boston University School of Medicine (A.S.B., R.S.V., E.J.B., C.S.K., P.A.W., J.R.R., S.S.), MA; and University of California (C.D.), Davis School of Medicine, Sacramento. ashkan.shoamanesh@phri.ca. 2. From McMaster University (A.S.), Hamilton, Canada; Harvard Medical School (A.S.), Boston; Boston University School of Public Health (S.R.P., A.S.B.); Boston University School of Medicine (A.S.B., R.S.V., E.J.B., C.S.K., P.A.W., J.R.R., S.S.), MA; and University of California (C.D.), Davis School of Medicine, Sacramento.
Abstract
OBJECTIVE: We investigated the association between circulating biomarkers of inflammation and MRI markers of small vessel disease. METHODS: We performed a cross-sectional study relating a panel of 15 biomarkers, representing systemic inflammation (high-sensitivity C-reactive protein, interleukin-6, monocyte chemotactic protein-1, tumor necrosis factor α, tumor necrosis factor receptor 2, osteoprotegerin, and fibrinogen), vascular inflammation (intercellular adhesion molecule 1, CD40 ligand, P-selectin, lipoprotein-associated phospholipase A2 mass and activity, total homocysteine, and vascular endothelial growth factor), and oxidative stress (myeloperoxidase) to ischemic (white matter hyperintensities/silent cerebral infarcts) and hemorrhagic (cerebral microbleeds) markers of cerebral small vessel disease (CSVD) on MRI in 1,763 stroke-free Framingham offspring (mean age 60.2 ± 9.1 years, 53.7% women). RESULTS: We observed higher levels of circulating tumor necrosis factor receptor 2 and myeloperoxidase in the presence of cerebral microbleed (odds ratio [OR] 2.2, 95% confidence interval [CI] 1.1-4.1 and OR 1.5, 95% CI 1.1-2.0, respectively), higher levels of osteoprotegerin (OR 1.1, 95% CI 1.0-1.2), intercellular adhesion molecule 1 (OR 1.7, 95% CI 1.1-2.5), and lipoprotein-associated phospholipase A2 mass (OR 1.5, 95% CI 1.1-2.1), and lower myeloperoxidase (OR 0.8, 95% CI 0.7-1.0) in participants with greater white matter hyperintensity volumes and silent cerebral infarcts. CONCLUSIONS: Our study supports a possible role for inflammation in the pathogenesis of CSVD, but suggests that differing inflammatory pathways may underlie ischemic and hemorrhagic subtypes. If validated in other samples, these biomarkers may improve stroke risk prognostication and point to novel therapeutic targets to combat CSVD.
OBJECTIVE: We investigated the association between circulating biomarkers of inflammation and MRI markers of small vessel disease. METHODS: We performed a cross-sectional study relating a panel of 15 biomarkers, representing systemic inflammation (high-sensitivity C-reactive protein, interleukin-6, monocyte chemotactic protein-1, tumor necrosis factor α, tumor necrosis factor receptor 2, osteoprotegerin, and fibrinogen), vascular inflammation (intercellular adhesion molecule 1, CD40 ligand, P-selectin, lipoprotein-associated phospholipase A2 mass and activity, total homocysteine, and vascular endothelial growth factor), and oxidative stress (myeloperoxidase) to ischemic (white matter hyperintensities/silent cerebral infarcts) and hemorrhagic (cerebral microbleeds) markers of cerebral small vessel disease (CSVD) on MRI in 1,763 stroke-free Framingham offspring (mean age 60.2 ± 9.1 years, 53.7% women). RESULTS: We observed higher levels of circulating tumor necrosis factor receptor 2 and myeloperoxidase in the presence of cerebral microbleed (odds ratio [OR] 2.2, 95% confidence interval [CI] 1.1-4.1 and OR 1.5, 95% CI 1.1-2.0, respectively), higher levels of osteoprotegerin (OR 1.1, 95% CI 1.0-1.2), intercellular adhesion molecule 1 (OR 1.7, 95% CI 1.1-2.5), and lipoprotein-associated phospholipase A2 mass (OR 1.5, 95% CI 1.1-2.1), and lower myeloperoxidase (OR 0.8, 95% CI 0.7-1.0) in participants with greater white matter hyperintensity volumes and silent cerebral infarcts. CONCLUSIONS: Our study supports a possible role for inflammation in the pathogenesis of CSVD, but suggests that differing inflammatory pathways may underlie ischemic and hemorrhagic subtypes. If validated in other samples, these biomarkers may improve stroke risk prognostication and point to novel therapeutic targets to combat CSVD.
Authors: Charles DeCarli; Joseph Massaro; Danielle Harvey; John Hald; Mats Tullberg; Rhoda Au; Alexa Beiser; Ralph D'Agostino; Philip A Wolf Journal: Neurobiol Aging Date: 2005-04 Impact factor: 4.673
Authors: Aleksandra Pikula; Alexa S Beiser; Charles DeCarli; Jayandra J Himali; Stephanie Debette; Rhoda Au; Jacob Selhub; Geoffrey H Toffler; Thomas J Wang; James B Meigs; Margaret Kelly-Hayes; Carlos S Kase; Philip A Wolf; Ramachandran S Vasan; Sudha Seshadri Journal: Circulation Date: 2012-03-28 Impact factor: 29.690
Authors: Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Lloyd E Chambless; Merle Myerson; Kenneth K Wu; A Richey Sharrett; Eric Boerwinkle Journal: Arch Intern Med Date: 2005-11-28
Authors: Joseph A Vita; Marie-Luise Brennan; Noyan Gokce; Shirley A Mann; Marlene Goormastic; Mehdi H Shishehbor; Marc S Penn; John F Keaney; Stanley L Hazen Journal: Circulation Date: 2004-08-23 Impact factor: 29.690
Authors: Aleksandra Pikula; Alexa S Beiser; Tai C Chen; Sarah R Preis; Demetrios Vorgias; Charles DeCarli; Rhoda Au; Margaret Kelly-Hayes; Carlos S Kase; Philip A Wolf; Ramachandran S Vasan; Sudha Seshadri Journal: Stroke Date: 2013-08-08 Impact factor: 7.914
Authors: Michael O Breckwoldt; John W Chen; Lars Stangenberg; Elena Aikawa; Elisenda Rodriguez; Shumei Qiu; Michael A Moskowitz; Ralph Weissleder Journal: Proc Natl Acad Sci U S A Date: 2008-11-14 Impact factor: 11.205
Authors: Tom Jeerakathil; Philip A Wolf; Alexa Beiser; Joseph Massaro; Sudha Seshadri; Ralph B D'Agostino; Charles DeCarli Journal: Stroke Date: 2004-06-24 Impact factor: 7.914
Authors: M O Giwa; J Williams; K Elderfield; N S Jiwa; L R Bridges; R N Kalaria; H S Markus; M M Esiri; A H Hainsworth Journal: Neurology Date: 2011-12-14 Impact factor: 9.910
Authors: Keenan A Walker; B Gwen Windham; Melinda C Power; Ron C Hoogeveen; Aaron R Folsom; Christie M Ballantyne; David S Knopman; Elizabeth Selvin; Clifford R Jack; Rebecca F Gottesman Journal: Neurobiol Aging Date: 2018-04-04 Impact factor: 4.673
Authors: Christa Watson; Edgar Busovaca; Jessica M Foley; I Elaine Allen; Christopher G Schwarz; Neda Jahanshad; Talia M Nir; Pardis Esmaeili-Firidouni; Benedetta Milanini; Howard Rosen; Owen T Carmichael; Paul M Thompson; Victor G Valcour Journal: J Neurovirol Date: 2017-01-18 Impact factor: 2.643
Authors: Priscila Corraini; Victor W Henderson; Anne G Ording; Lars Pedersen; Erzsébet Horváth-Puhó; Henrik T Sørensen Journal: Stroke Date: 2016-11-29 Impact factor: 7.914
Authors: Martha M Werler; Samantha E Parker; Klaus Hedman; Mika Gissler; Annukka Ritvanen; Heljä-Marja Surcel Journal: Am J Epidemiol Date: 2016-11-17 Impact factor: 4.897
Authors: Zachary P Fricker; Alison Pedley; Joseph M Massaro; Ramachandran S Vasan; Udo Hoffmann; Emelia J Benjamin; Michelle T Long Journal: Clin Gastroenterol Hepatol Date: 2018-11-23 Impact factor: 11.382